LIQUIDSEQ BREAST & OVARIAN CANCER PANEL (93 GENES)

What is Liquidseq Breast and Ovarian cancer panel test?

Liquidseq Breast and Ovarian cancer panel test is a liquid biopsy genetic test that analyzes 93 genes associated with breast and ovarian cancers. It uses a blood sample (circulating tumor DNA or ctDNA) to detect genetic mutations linked to cancer risk, progression, or treatment response. Unlike traditional tissue biopsies, this test is minimally invasive and can capture tumor genetics in real-time.  This panel covers a broad range of high-, moderate-, and low-risk genes related to hereditary cancer syndromes and somatic mutations.

Why consider is Liquidseq Breast and Ovarian cancer panel test?

• To detect genetic mutations non-invasively in patients with suspected or diagnosed breast/ovarian cancer.
• To guide targeted therapy options based on mutation status.
• To monitor treatment response and detect resistance mutations.
• To identify hereditary risk factors and somatic mutations simultaneously.
• Useful when tissue biopsy is difficult or risky.

Who should get tested for Liquidseq Breast and Ovarian cancer panel test?

• Patients with breast or ovarian cancer who need molecular profiling for treatment planning.

• Individuals unable to undergo tissue biopsy or where tissue biopsy is insufficient.
• Patients with advanced or metastatic disease for monitoring tumor genetics over time.
• Those suspected to have hereditary cancer risk where blood-based genetic testing is preferred.
• Patients considering enrollment in clinical trials requiring genetic mutation status.

More Information

OTHER NAMES: Liquid Biopsy Breast & Ovarian Panel, Circulating Tumor DNA (ctDNA) Breast/Ovarian Cancer Panel, Comprehensive Liquid Genetic Panel for Breast and Ovarian Cancer

Breast cancer is the uncontrolled growth of cells in breast tissue, often starting in ducts or lobules.  Ovarian cancer originates in the ovaries, fallopian tubes, or peritoneum, often detected late due to subtle symptoms. Genetic mutations: BRCA1, BRCA2, and other hereditary genes raise risk for both cancers.